Mindray Medical International Limited Corporate Presentation. January 2014

Transcription

1 Mindray Medical International Limited Corporate Presentation January 2014

2 Disclaimer This material contains "forward looking statements" within the meaning of the safe harbor provisions of the U. S. Private Securities Litigation Reform Act of Statements contained herein and in our t Preliminary 2013 Operating Results and 2014 net Revenue Guidance press release that are not historical facts, including, without limitation, the following statements about Mindray s expectation of its net revenue for the year ended December 31, 2013 to be approximately US$1,212 million, representing a year-over-year growth of approximately 14.3%, Mindray s anticipation of its 2013 non-gaap net income to be approximately US$236 million, growing approximately 11.5% year-over-year based on the estimated full year revenue, Mindray s assumption of a corporate income tax rate of 15% applicable to the Shenzhen subsidiary, Mindray s anticipation that its net revenue will grow at least 15% year-over-year for the year 2014, Mindray s expectation that Zonare transaction would facilitate its entry into the high-end ultrasound business, Mindray s forecast of its 2014 revenue to increase at least 15 %, higher than its sales growth in 2013, Mindray s anticipation that Western Europe and certain emerging countries will lead its top-line growth and the market sentiment in China will gradually improve, Mindray s intension to launch another seven to 10 new products to further broaden its product offerings, Mindray s plan to invest in R&D and enhance its sales and service platforms in key markets to strengthen its long-term competitive position, statement that Mindray s management will continue to pursue growth through M&As and other collaboration opportunities as well as statements about Mindray s 2013 preliminary results, 2014 net revenue guidance, 2014 market outlook and growth plan for 2014 are forward-looking statements. Forward-looking statements represent only the company's beliefs and predictions regarding future events, many of which, by their nature, are inherently uncertain and outside of the company's control. Our actual results and financial condition and other circumstances may differ materially from the anticipated results and financial condition indicated in these forward-looking statements due to a variety of risk, uncertainties and factors, including, without limitation, the growth and expected growth of the medical device market in China and internationally; relevant government policies and regulations relating to the medical device industry; market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; our ability to settle disputes with our customers and suppliers; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 5 of our annual report on Form 20-F which was filed with the Securities and Exchange Commission on April 8, Our results of operations for the fourth quarter of 2013 and for fiscal year 2013 are not necessarily indicative of our operating results for any future periods. The financial information contained in these materials should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. Any projections in these materials are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this presentation. 1

3 Who We Are Mindray is a leading developer, manufacturer and marketer of medical devices worldwide, creating value and driving growth through: Meeting the needs of hospitals and health systems in various countries around the world Constant innovation driven by a world class R&D platform and a vertically integrated business model Leveraging its leading position in the fast-growing China market while expanding its global presence 2

4 Who We Are Established in 1991 Headquarters in Shenzhen, China 11 R&D centers, 29 subsidiaries in more than 20 countries Over US$1 billion in annual sales Over 7,800 employees globally Export to more than 190 countries Listed on the NYSE 3

5 A Global Player in Medical Technologies 2003 Total Revenues 2012 Total Revenues Emerging Markets 17% Emerging Markets 34% Developed Markets 8% US$ 59mm US$ 1,060mm 704mm China 45% China 75% Developed Markets 21% Note: Emerging markets represent all countries except China and the developed markets. Developed markets refer to the North American and Western European countries. 4

6 Committed to Innovation Invest 10% of annual sales revenue Patents 1000 Talent 1,800 R&D New products 7-10 annually Master or PhD 63% 5

7 11 Worldwide R&D Centers Mountain View, CA, USA Mahwah, NJ, USA Stockholm, Sweden Beijing, China Miami, FL, USA Nanjing, China Seattle, USA Seattle, WA, USA Shenzhen, China Chengdu, China Xi an, China Shanghai, China 6

8 Expanding Product Offerings Launch Time Patient Monitoring & Life Support Products Ventilator: 3B Infusion Pump & Syringe Pump: 1B Defibrillator & Surgical Equipment: 9.9B Anesthesia Machine: 1.1B Patient Monitoring: 3B Addressable Market Size (US$) Total addressable market size worldwide : ~ 18.0B Launch Time In-Vitro Diagnostic Products 2013 Immunoassay: 7.6B 2012 Coagulation Analysis: 1.7B 2011 Microbiology Analysis: 2.3B 2011 Urine Analysis: 1.0B 2001 Biochemistry Analysis: 7.6B 1998 Hematology Analysis: 1.9B Addressable Market Size (US$) Total addressable market size worldwide: ~22.1B Launch Time Medical Imaging Systems 2010 Magnetic Resonance Imaging: 2.5B 2008 Digital Radiography: 2.3B 2000 Ultrasound: 5.5B Addressable Market Size (US$) Total addressable market size worldwide: ~ 10.3B Launch Time Other Products 2012 Endoscopes : 5.1B 2012 Orthopedics : 30B 2011 PACS: 3.5B Addressable Market Size (US$) Total addressable market size worldwide: ~38.6B 7 Source: Internal estimates

9 M&A Road Map Product segment Patient Monitoring & Life Support Announcement Time Target Products 1Q 2008 Datascope Corp Patient monitors 1Q 2011 Shenzhen Shenke Medical Instrument Technical Development Infusion pumps, syringes and infusion monitoring systems 2Q 2011 Suzhou Hyssen Electronics Urine analyzers In-Vitro Diagnostic 4Q 2011 Hunan Changsha Tiandiren Biotech Microbiology analysis solutions 3Q 2012 Beijing Precil Instrument Coagulation analyzers and related products 4Q 2013 Shanghai Long Island Biotec. Coagulation analysis reagents Medical Imaging Systems 2Q 2013 ZONARE Medical Systems Ultrasound systems Others 4Q 2011 Zhejiang Greenlander Information Technology Healthcare IT solutions (PACS, RIS) 2Q 2012 Hangzhou Optcla Medical Instrument Rigid endoscopes, related surgical instruments and consumables 2Q 2012 Wuhan Dragonbio Surgical Implant Orthopedics products (trauma, spine, joints and other surgical products) 3Q 2012 Shanghai Medical Optical Instrument Flexible endoscopes and related surgical instruments 2Q 2013 Ulco Medical Australia-based former distributor of Mindray 8

10 Investment Highlights A world-class organization rooted in the world s fastest-growing market China s leading domestic brand in three main product areas, backed by global research centers in the U.S., Europe and China One of the most comprehensive sales and service infrastructure in China, reaching all major cities from local sales offices with distributors A robust growth track record in emerging markets A high-quality brand that is appealing to value-seeking customers Ongoing sales and marketing investments in markets with promising growth prospects Long-term focus on growth, profitability and cash generation US$ mm Revenue Non-GAAP Net income Cash and cash equivalents and short-term/restricted investments , Notes: 1. Non-GAAP figures exclude sharebased compensation expenses, acquired intangible assets amortization expenses, in-progress research and development expenses, realignment costs - post acquisition, dispute charges, dispute related legal fees, as well as income from early termination of contract, all net of related tax impact. 2. Restricted cash and restricted investments related to purchase consideration in connection with our acquisition being held on escrow accounts are excluded. 9

11 2013 Preliminary Results USD mm ~14.3% ~1,212 USD mm 1,060 ~ 11.5% 212 ~236 Revenues Non-GAAP Net Income Notes: The non-gaap net income figure excludes the $19.4 million corporate income tax reduction recognized in the first quarter of The above figures for 2013 are unaudited and remain subject to the finalization of the company's year-end closing, reporting and audit processes. Non-GAAP net income represents net income reported in accordance with GAAP, adjusted for the effects of share-based compensation, amortization of acquired intangible assets, dispute charges and withholding tax for intra-group transfer, all net of related tax impact. 10

12 Achievement Highlights in 2013 Delivered consistent year-over-year double-digit growth with sales increase of approximately 14.3% and non-gaap net income growth of around 11.5%. Successfully raised our brand recognition and enhanced our reputation in Western European markets, thanks to our attractive products and improving sales and service capabilities; more leading hospitals are becoming Mindray s customers. Key emerging markets continued to perform well, as a result of consistent sales and marketing investments. In-vitro diagnostic segment continued to record strong sales growth, along with significant ramp-up in higher-margin reagents sales. Exceeded product development goal by launching 11 new products, including the first-generation chemiluminescence immunoassay product, the CL-2000i. Completed two overseas acquisitions, including ZONARE, a U.S. high-end ultrasound technology provider, and Ulco Medical Pty. Ltd., an Australia-based former distributor of Mindray; the integration of prior acquisitions are also well on track. 11

13 Strong Product Development Patient Monitoring & Life Support Products Patient monitors In-Vitro Diagnostic Products Chemiluminescence immunoassay analyzer Medical Imaging Systems Cart-based color ultrasound Defibrilator ECGs Hematology analyzer Digital Radiography systems Infusion pump Syringe pump Reagents 12

14 2014 Market Outlook China: Weak market sentiment to persist in the short term. However, the long term private and government healthcare spending environment remains favorable Emerging markets: Political instability and currency risks in some regions, offset by private and public opportunities in other countries Developed markets: Gradual economic improvement in Western Europe and stabilizing business for our North American division. However, the macro uncertainties remain as potential headwind in the US market 13

15 2014 Net Revenue Guidance USD mm 15% ~1,212 1,393 Net Revenue 2014 Full-Year Guidance 15% YoY 1,060 Revenues P 2014 Guidance 14

16 Growth Plans for 2014 To capture growth opportunities in the domestic China market, Mindray plans to: Strengthen our position in the public sector and seize more opportunities in the fast-growing private markets Continue to optimize sales, marketing and service platforms To enhance our presence in the emerging markets, Mindray intends to: Continue to increase investment in our top emerging countries Further improve our localization efforts to suit different market and customer needs To improve our performance in the developed markets, Mindray aims to: Introduce new products and increase brand awareness Further optimize sales channels and improve service capabilities Focus on R&D investment in technology and product development while improving efficiency Launch seven to 10 new products to broaden product offerings across different market segments Continue to actively seek M&A opportunities globally 15

17 16 Healthcare within Reach